Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Z-endoxifen
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Atossa Therap
Drug class:
Selective estrogen receptor modulator, Selective estrogen receptor α inhibitor, PKCβ inhibitor
Related drugs:
‹
toremifene (4)
lasofoxifene (3)
Z-endoxifen hydrochloride (2)
afimoxifene (1)
acolbifene (0)
LY353381 (0)
ormeloxifene (0)
raloxifene hydrochloride (0)
H3B-6545 (5)
TAS-108 (0)
enzastaurin (3)
MS-553 (0)
toremifene (4)
lasofoxifene (3)
Z-endoxifen hydrochloride (2)
afimoxifene (1)
acolbifene (0)
LY353381 (0)
ormeloxifene (0)
raloxifene hydrochloride (0)
H3B-6545 (5)
TAS-108 (0)
enzastaurin (3)
MS-553 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
doxorubicin hydrochloride + Z-endoxifen
Sensitive: D – Preclinical
doxorubicin hydrochloride + Z-endoxifen
Sensitive
:
D
doxorubicin hydrochloride + Z-endoxifen
Sensitive: D – Preclinical
doxorubicin hydrochloride + Z-endoxifen
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login